Abstract: The invention relates to an impeller (1) for a fan, in particular an axial or radial fan having a hub (2) for connecting the impeller (1) to a drive motor and having fan blades (6) which are arranged circumferentially around the hub (2) and having pockets (9) in the hub region, having balance weights (15) which can be fastened therein, aligned in the axial direction. The balance weights (15) are made of U-shaped, bent weight clips made of spring-elastic material, having at least two opposite clip legs extending parallel to each other which are connected to each other via a bend section, and comprise a clamping gap between the clip legs. One of the clip legs extends within the pockets (9) and the other clip leg extends outside of the pockets (9), such that there is a clamping seat on a pocket wall (12) extending in the clamping gap.

Abstract: A balancing weight to balance a blower wheel. The balancing weight is constructed in two pieces consisting of a spring clip and a supplemental weight. The spring clip features a retaining section for securing on the blower wheel and a receptacle section for mounting the supplemental weight.

Abstract: The invention relates to an impeller (1) for a fan, in particular an axial or radial fan having a hub (2) for connecting the impeller (1) to a drive motor and having fan blades (6) which are arranged circumferentially around the hub (2) and having pockets (9) in the hub region, having balance weights (15) which can be fastened therein, aligned in the axial direction. The balance weights (15) are made of U-shaped, bent weight clips made of spring-elastic material, having at least two opposite clip legs extending parallel to each other which are connected to each other via a bend section, and comprise a clamping gap between the clip legs. One of the clip legs extends within the pockets (9) and the other clip leg extends outside of the pockets (9), such that there is a clamping seat on a pocket wall (12) extending in the clamping gap.

Abstract: A balancing weight to balance a blower wheel. The balancing weight is constructed in two pieces consisting of a spring clip and a supplemental weight. The spring clip features a retaining section for securing on the blower wheel and a receptacle section for mounting the supplemental weight.

Abstract: Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, —NHZR5 is at the ortho position to the CONH linker; —R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom, or an organic residue; R3 is a hydrogen or halogen atom or an organic group; R4 is a hydrogen or halogen atom or an organic group; Z is direct bond, >C?O, or —C(?O)NH—; —R5 is hydrogen or an optionally substituted organic group or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof. A process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Aurora kinases activity or IGF-1R activity, like cancer.

Abstract: There are provided thieno[2,3-c]pyrazole derivatives of formula (I), wherein A is an aryl or heteroaryl ring, on which the substituent-NHZR5 is at the ortho position to the CONH linker; R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom or an organic group; R4 is a hydrogen or halogen atom or an organic group; Z is direct bond, >C?O, or —C(?O)NH—; R5 is hydrogen or an organic group; or isomers, tautomers, carriers, metabolites, prodrugs, and pharamaceutically acceptable salts thereof. A process for their preparation and pharamaceutical compositions comprising them are also disclosed; the compounds of the invention may be useful, in theraphy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: The present invention provides a method of treating a mammal, including humans, suffering from tumour, comprising administering Compound 1 of the formula A or a pharmaceutically acceptable salt thereof, to said mammal by intravenous infusion, characterised in that Compound 1 is conveniently administered employing particular schedules, infusion times and doses which allow a more efficacious treatment. Compound 1 of formula A is an aurora inhibitor, chemical name N-{5-[(2R)-2-methoxy-2-phenylethanoyl]-1,4,5,6-tetrahydropyrrolo[3,4-c]pyrazol-3-yl}-4-(4-methylpiperazin-1-yl)benzamide, and the method is preferably for the treatment of patients having solid tumours or hematopoietic malignant tumours.

Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

Abstract: The present invention provides a therapeutic combination comprising (a) a compound 1 of formula (A) as set forth in the specification and (b) a BCR-ABL kinase inhibitor selected from the group consisting of Imatinib, Dasatinib, Nilotinib, Bosutinib and Inno-406, wherein the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt or any hydrate thereof.

Abstract: The invention provides low molecular weight compounds, namely 1H-thieno[2,3-c]pyrazoles, showing a high affinity for the ATP pocket of ABL tyrosine kinase. These compounds are thus ATP-competitive tyrosine kinase inhibitors displaying a significant inhibitory potency also, and in particular, towards BCR-ABL inhibitor-resistant T315I ABL mutants. The compounds of the invention find a useful application in the treatment of BCR-ABL inhibitor-resistant ABL-mediated diseases, such as Imatinib-resistant chronic myelogenous leukemia. Moreover, the invention provides a screening method for the identification of compounds capable of binding the ATP pocket of a kinase protein, in particular of the T315I mutant ABL kinase.

Abstract: Furo[3,2-c]pyrazole derivatives of formula (I) as defined in the description, and pharmaceutically acceptable salts thereof, wherein A is an aryl or heteroaryl ring, —NHZR5 is at the ortho position to the CONH linker; —R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom, or an organic residue; R3 is a hydrogen or halogen atom or an organic group; R4 is a hydrogen or halogen atom or an organic group; Z is direct bond, >C?O, or —C(?O)NH—; —R5 is hydrogen or an optionally substituted organic group or isomers, tautomers, carriers, metabolites, prodrugs, and pharmaceutically acceptable salts thereof. A process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, in particular Aurora kinases activity or IGF-1R activity, like cancer.

Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: There are provided thieno[2,3-c]pyrazole derivatives of formula (I), wherein A is an aryl or heteroaryl ring, on which the substituent-NHZR5 is at the ortho position to the CONH linker; R1 and R2 are the same or different and, independently from each other, represent a hydrogen atom or an organic group; R4 is a hydrogen or halogen atom or an organic group; Z is direct bond, >C?O, or —C(?O)NH—; R5 is hydrogen or an organic group; or isomers, tautomers, carriers, metabolites, prodrugs, and pharamaceutically acceptable salts thereof. A process for their preparation and pharamaceutical compositions comprising them are also disclosed; the compounds of the invention may be useful, in theraphy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: The invention provides pyrido[2,3-d]pyrimidin-7(8H)-one telomerase inhibitors of the formula where R1, R2 are as defined herein. The invention also provides methods for preparing the compounds of formula I, methods of using the compounds to treat diseases such as cancer, and pharmaceutical compositions comprising the compounds.

Abstract: The present invention provides a human polypeptide homolog of P21-activated kinase (PAK) polynucleotides which identify and encode PAK5 serine/threonine kinase. In addition, the invention provides expression vectors, host cells and methods for its production. The invention also provides methods for the identification of PAK5 agonists/antagonists, useful for the treatment of human diseases and conditions.

Abstract: Pyrrolo[3,4-c]pyrazole derivatives of formula (I) and pharmaceutically acceptable salts thereof, as defined in the specification, process for their preparation and pharmaceutical compositions comprising them are disclosed; the compounds of the invention may be useful, in therapy, in the treatment of diseases associated with a disregulated protein kinase activity, like cancer.

Abstract: The present invention relates to know and novel substituted aurones active as telomerase inhibitors, to their use as therapeutic agents, in particular as antitumoral agents, to a process for their preparation as to pharmaceutical compositions comprising them.

Abstract: The present invention relates to benzopyranone derivative, to methods for treating telomerase-modulated diseases, in particular cancers, with said derivatives, to a process for their preparation, to their use as medicaments and to pharmaceutical compositions comprising them.